Plexus (PLXS) Q2 2026 Earnings Call Transcript

Plexus reported fiscal Q2 revenue of $1.164 billion, up 19% year over year, with non-GAAP EPS of $2.05 and operating margin of 6.0%, both above guidance. Management raised fiscal 2026 expectations to mid-teens or greater revenue growth and at least a 6% non-GAAP operating margin, while also guiding Q3 revenue to $1.2 billion-$1.25 billion. Cash flow was positive at $16 million, the company repurchased 109,000 shares for $20.6 million, and the qualified opportunity funnel expanded 11% to $4 billion.

Analysis

PLXS is transitioning from a cyclical EMS name to a compounding share-gain story, and the second-order effect is that capacity discipline is now a competitive weapon. The company is effectively converting throughput gains into avoided capex and better returns on incremental revenue, which should keep ROIC well above cost of capital even as growth accelerates. That combination is rare in hardware-heavy manufacturing and implies peers with lower service mix or weaker working-capital discipline will be forced to spend more just to defend share.

The market is underappreciating how much of the current upside is self-reinforcing. New wins today feed the funnel tomorrow, but the bigger bull case is that customer concentration risk is being diluted by broader program breadth across defense, industrial, and medtech, lowering the probability that a single end-market slowdown breaks the thesis. The supply-chain tightening actually helps PLXS near term because firms with better sourcing systems and higher customer trust tend to absorb allocation first, while smaller competitors face longer ramps and more missed build schedules.

The main risk is not demand; it is execution during the ramp phase. Margin expansion can stall for 2-3 quarters if working capital needs jump faster than receivables conversion, particularly if the company has to pre-buy constrained components or accelerate site investments. A softer macro would also hit the longer-dated wins pipeline with a lag of 2-4 quarters, so the stock likely trades on guidance credibility and cash conversion rather than headline revenue alone.

Contrarian take: the move may be underdone if investors still model PLXS like a low-teens-growth, low-margin EMS provider rather than a mid-teens grower with structural operating leverage. The re-rating lever is not just EPS; it is the market accepting a higher terminal margin and lower capital intensity. If management executes on cash cycle normalization by year-end while holding 6%+ op margin, multiple expansion should follow.

Key Decisions for Investors

• Long PLXS into any 3-5% pullback over the next 1-2 weeks; risk/reward improves if the market fades the guide as 'too good to last' despite evidence of self-funded growth and rising ROIC.
• Buy PLXS Jan-2027 call spreads to express the thesis that the stock rerates on durable 6%+ operating margins and mid-teens revenue growth; target payoff is strongest if FY27 guidance confirms continued share gains.
• Pair trade: long PLXS / short a lower-quality EMS peer with weaker working-capital discipline and lower mix of defense/industrial exposure; this isolates the valuation gap from execution quality and capex intensity.
• If already long, sell covered calls against 10-15% of the position into post-earnings strength; near-term upside is likely capped by cash-cycle and ramp skepticism, while core upside is a FY27 rerate.
• Monitor for a sustained rise in cash cycle above low-70s days; if that happens for two consecutive quarters, reduce exposure because the market will start discounting the growth story as balance-sheet intensive rather than self-funded.